Review

Mechanisms of inflammation in gout

N. Dalbeth and D. O. Haskard

The clinical manifestations of gout are due to interactions between monosodium urate (MSU) crystals and local tissues. This review article outlines recent advances in the understanding of the mechanisms of inflammation in gout. We focus on the cellular response to MSU crystals during acute arthritis, termination of the acute attack and maintenance of asymptomatic hyperuricaemia, and chronic tophaceous disease. We then propose a unifying model of gout involving the differential role of mononuclear phagocytes in the regulation of the inflammatory response to MSU crystals.

The acute gout attack

Initiation of the acute gout attack

The acute attack of gout has all the hallmarks of an acute inflammatory response. Histological examination of the synovium in acute gout shows lining layer hyperplasia and intense infiltration of the membrane by neutrophils, mononuclear phagocytes and lymphocytes [1, 2]. Acute attacks of gout are often triggered by specific events, such as trauma, surgery, intercurrent illness, excess alcohol intake or drugs that alter serum urate levels. Such events may stimulate de novo formation of MSU crystals or may trigger release of microcrystals from preformed deposits within the joint. Although supersaturation of interstitial fluid with MSU is required for the development of crystals, other factors, such as local temperature and pH within the joint, also influence whether crystal formation occurs [3]. Debris within the synovial cavity may provide an initial nucleus for early crystal development [4]. In addition, MSU crystal nucleation may be stabilized by albumin and by immunoglobulin [5, 6]. Depletion of endogenous mast cells has been found to significantly inhibit neutrophil influx in the murine model of acute arthritis, termination of the acute attack and maintenance of asymptomatic hyperuricaemia, and chronic tophaceous disease. We then propose a unifying model of gout involving the differential role of mononuclear phagocytes in the regulation of the inflammatory response to MSU crystals.

Leucocyte recruitment

A central component of acute inflammation involves the activation of vascular endothelial cells, leading to vasodilatation with increased blood flow, increased permeability to plasma proteins and the recruitment of leucocytes into the tissues. Initial endothelial activation with expression of adhesion molecules such as E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) may be caused by factors such as TNF-α released by mast cells [8] (see above), and it is likely that endothelial activation is then amplified by factors released by leucocytes entering the tissues and encountering crystals. Experiments using human umbilical vein endothelial cells have shown that MSU-stimulated monocyte supernatants induce expression of E-selectin, ICAM-1 and VCAM-1, and that this effect is entirely attributable to release of TNF-α and interleukin (IL)-1β [9]. Moreover, in a pig model of MSU-induced arthritis, blockade of TNF-α significantly inhibited E-selectin expression and neutrophil recruitment [9]. Leucocyte recruitment is also likely to be enhanced by the local generation of chemotactic factors such as C5a, S100A8/A9 and IL-8 [10, 11]. In a rabbit model of MSU crystal-induced arthritis, inflammation was inhibited using an anti-IL-8 antibody [12] (see below). Furthermore, neutrophil influx following injection of MSU crystals into a subcutaneous air pouch was found to be attenuated in mice deficient in the IL-8 receptor CXCR2 [13].

Amplification

Native uncoated MSU crystals can activate leucocytes, but may also be directly membranolytic [14]. In addition, a number of interstitial fluid proteins bind MSU crystals, including immunoglobulins (IgG and IgM), adhesion proteins (e.g. fibronectin) and complement proteins, resulting in protection from lysis, leading to both local arthritis and a systemic acute phase response. Amplification of the complement system is usually very low in normal uninflamed synovial fluid, but is greatly increased in inflamed synovial fluid obtained from patients with acute gout [17]. MSU crystals activate both the classical and the alternative complement pathway in vitro [18, 19]. A number of complement components, including C1q, C1r and C1s, have been shown to bind MSU crystals [15]. Although MSU crystals also avidly bind IgG, activation of the classical pathway does not require the presence of immunoglobulin, suggesting that MSU crystals directly activate the classical pathway [20]. Activation of the complement pathways leads to the elaboration of C3a and C5a, which act as leucocyte chemoattractants. Furthermore, the coating of MSU crystals with iC3b provides a ligand for interactions with leucocytes (see below). Interestingly, activation of the terminal membrane attack complex of
Mechanisms of inflammation in gout

1091

complement appears to play a major role in the generation of IL-8 in response to MSU crystals, and thus neutrophil recruitment into the acutely inflamed joint in gout [21].

Kininogen. Formation of the vasoactive peptide bradykinin may also contribute to amplification of the inflammatory response to MSU crystals. In addition to immunoglobulins and complement components, urate crystals bind plasma kininogen [15]. Bradykinin is formed by the interaction with high molecular weight kininogen on urate crystals, and factor XII and prekallikrein. Bradykinin is able to activate endothelial cells and promote vasodilatation, vascular permeability and arachidonic acid metabolism. In addition, this peptide stimulates sensory nerve endings to induce pain (reviewed in [22]). The relevance of this system to the pathogenesis of the acute gout attack has been emphasized by studies of Brown Norway rats that are devoid of high molecular weight kininogen and poor in kallikrein. In these rats, the inflammatory response to MSU crystals is much reduced [23]. Similarly, bradykinin antagonists also suppress the inflammatory response to urate crystals in vivo [24].

Cellular amplification. MSU crystals can interact with cells by phagocytosis or direct interaction with cell surface receptors. Phagocytosis of MSU crystals is greatly promoted by opsonization by IgG or complement components. Intense infiltration of neutrophils into both synovial membrane and fluid is the hallmark of acute gout, and these cells provide the main cellular mechanism of inflammatory amplification. In the dog, MSU crystal-induced synovitis can be inhibited by depletion of neutrophils, and this can be reversed by neutrophil reconstitution [25]. A number of neutrophil surface receptors are probably involved in mediating responses to MSU crystals [26, 27], and these include CR3 (CD11b/CD18) and FcγRIII (CD16), which bind crystal-bound iC3b and IgG, respectively [28]. The consequent recruitment of neutrophil interaction with MSU crystals include the synthesis and release of a large variety of mediators that promote the vasodilatation, erythema and pain associated with the acute gout attack. These include reactive oxygen species such as superoxide, hydrogen peroxide and singlet oxygen, nitric oxide, leukotriene B4, prostaglandin (PG) E₂, anti-microbial peptides, enzymes, IL-1, and chemokines such as S100A8, S100A9 and IL-8 [29–35].

Following phagocytosis of MSU crystals, monocytes also become activated, resulting in expression of a number of proinflammatory genes, including IL-1, TNF-α, IL-6, IL-8 and cyclooxygenase-2 [36–40].

Although the generation of acute inflammatory mediators is usually associated with infiltrating leucocytes, resident stromal cells may also contribute mediators to the response. Thus, synovial fibroblasts can phagocytose MSU crystals and respond by releasing arachidonic acid metabolites such as PGE₂ [41].

Recent work has clarified the signalling pathways involved in cellular activation in response to MSU crystals. MSU crystal-induced activation of Src family tyrosine kinases, Syk tyrosine kinase and the ERK1/2, p38 and JNK mitogen-activated protein kinases (MAPK) regulates cellular responses during the acute gout attack [40, 42–45]. Within mononuclear phagocytes, the ERK1/2 MAPK pathway plays a particular role in activator protein-1 (AP-1) and nuclear factor-κB (NF-κB) activation, and subsequent production of proinflammatory mediators following stimulation with MSU crystals [45, 46].

Drugs currently used for the treatment of the acute gout attack inhibit amplification of the inflammatory response to MSU crystals. For example, colchicine, a drug with specific clinical efficacy in acute gout [47], inhibits neutrophil recruitment and activation [32, 33, 48, 49]. Non-steroidal anti-inflammatory agents (NSAIDs) prevent release of PGE₂ and other arachidonic acid metabolites from various cells in response to MSU crystals [41, 50]. Through targeting of other pathways involved in the initiation and amplification phases, novel treatments may be identified to prevent or treat the acute gout attack.

Pain in the acute gout attack

A hallmark of the acute crystal arthropathies is severe joint pain. This pain may be due to a number of factors, including local production of prostaglandins and bradykinin, and sensitization of nociceptors [51]. When unmyelinated nerve fibres are stimulated, there is release of neuropeptides such as substance P. Substance P results in vasodilatation, plasma extravasation, leucocyte recruitment, mast cell degranulation, and release of PGs and cytokines. Following intra-articular injection of MSU crystals into domestic chick ankle joints, there is rapid depletion of substance P from peripheral nerves in the synovial and subsynovial tissue [52]. These data implicate substance P as a potential mediator of pain and inflammation in acute gout.

Termination of the acute attack and maintenance of asymptomatic hyperuricaemia

Even in the absence of treatment, the acute inflammatory response in gout is typically self-limiting over 7–10 days. Furthermore, it is well recognized that MSU crystals can be found in the asymptomatic joints of patients with hyperuricaemia [53–55]. These observations imply a balance between the factors within the joint that maintain the non-inflamed state in the presence of MSU crystals and the proinflammatory response that accompanies an acute gout attack.

Stages of the inflammatory response in skin

Injection of MSU crystals into human skin leads to an erythematous reaction that is maximal at 24h and then spontaneously subsides [56]. A similar response is demonstrated in pig skin, and this model has been used to study the kinetics of endothelial activation and leucocyte trafficking in response to MSU crystals [57]. In this model, the inflammatory response involves several distinct phases (Fig. 1). First, endothelial E-selectin expression increases over 2–6h, closely paralleled by accumulation of neutrophils and mononuclear phagocytes, and albumin leakage. Secondly, leucocyte accumulation rapidly declines despite persisting E-selectin expression. Thirdly, after peaking 8h after crystal injection, E-selectin expression falls despite increasing erythema and induration. Finally, the clinical manifestations of inflammation subside despite the continued presence of MSU crystals in the tissue. These observations suggest that down-regulation of the acute inflammatory response may start with the suppression of further leucocyte recruitment by the autoregulation of endothelial activation, possibly through endogenous mechanisms of inactivating NF-κB and other transcription factors that mediate the response to TNF-α and IL-1. However, further mechanisms of down-regulation must exist to account for the gradual loss of erythema after 24h.

Mediators of the resolution phase in acute gout

Changes in proteins that coat MSU crystals. Changes in the interstitial fluid proteins that coat MSU crystals may modify inflammation. This effect is at least partly due to lipoproteins containing apolipoproteins B and E [58, 59]. Apolipoprotein E is produced by macrophages and is enriched in inflammatory synovial fluid. Coating of MSU crystals by apolipoprotein E inhibits neutrophil granule release and has been demonstrated in patients with gout [59]. The physiological importance of protein coating has also been suggested by serial sampling of
MC3-R antagonist and can be reproduced by a MC3-R agonist. The MC3-R has been demonstrated in a murine model. The effects of melanocortin peptides occur through signalling via the five melanocortin receptors (MC-R). The MC3-R has been demonstrated in a murine model of MSU crystal-induced peritonitis, and on macrophages isolated from rat knee joints. ACTH has an anti-inflammatory effect on MSU-induced arthritis in the rat knee joint at a concentration that does not increase circulating corticosteroids. ACTH1-39 is also effective in adrenalectomized rats, confirming that this effect is not due to stimulation of adrenal corticosteroids. This anti-inflammatory action is dependent on signalling through the MC3-R, as the ACTH1-39 effect can be blocked by a selective MC3-R antagonist and can be reproduced by a MC3-R agonist.

**Fig. 1.** Kinetics of endothelial E-selectin expression, entry of neutrophils and mononuclear cells into the tissues, and erythema in pig skin after injection of MSU crystals. Reproduced from Haskard and Landis [81] with permission from Biomed Central Ltd.

Synovial fluid crystals from patients with acute gout, demonstrating that as inflammation subsides MSU crystals become coated with apolipoprotein B. Similar coating has been demonstrated on MSU crystals in resolving air-pouch inflammation [60]. Thus, displacement of proinflammatory IgG by apolipoproteins coating MSU crystals may contribute to resolution of the acute gout attack.

**Melanocortins.** Products of the hypothalamic-pituitary axis may also influence the resolution of the acute gout attack. The anti-inflammatory properties of the melanocortins, such as adrenocorticotrophic hormone 1-39 (ACTH1-39) and α-melanocyte-stimulating hormone (α-MSH), have been demonstrated in many experimental models. The effects of melanocortin peptides occur through signalling via the five melanocortin receptors (MC-R). The MC3-R has been demonstrated in a murine model of MSU crystal-induced peritonitis, and on macrophages isolated from rat knee joints. ACTH has an anti-inflammatory effect on MSU-induced arthritis in the rat knee joint at a concentration that does not increase circulating corticosteroids. ACTH1-39 is also effective in adrenalectomized rats, confirming that this effect is not due to stimulation of adrenal corticosteroids. This anti-inflammatory action is dependent on signalling through the MC3-R, as the ACTH1-39 effect can be blocked by a selective MC3-R antagonist and can be reproduced by a MC3-R agonist [61, 62].

**Peroxisome proliferator-activated receptor γ (PPAR-γ).** A member of the nuclear hormone receptor superfamily. This transcription regulator is expressed in a wide variety of cells, including mononuclear phagocytes, and may function as an important negative regulator of the inflammatory response. PPAR-γ ligands inhibit transcription of many proinflammatory genes, including TNF-α, IL-1 and IL-6, cyclooxygenase-2, inducible nitric oxide synthase and matrix metalloproteinases (MMPs). The clinical relevance of PPAR-γ in the resolution of acute gout episodes is suggested by experiments demonstrating that MSU crystals induce expression of PPAR-γ mRNA in human monocytes. PPAR-γ can be detected in monocytes by immunohistochemistry 12 h after exposure to MSU crystals. A natural ligand of PPAR-γ, 15-deoxy-PGJ2, is capable of inhibiting the production of TNF-α and IL-1β by MSU-stimulated monocytes, and also inhibits early cellular infiltration in the air pouch model [63].

PPAR-γ ligands also promote monocyte expression of CD36, a scavenger receptor for apoptotic cells [63]. Apoptotic neutrophils are rapidly and efficiently phagocytosed by tissue macrophages. This may protect tissues from damage due to autolysis and spillage of toxic neutrophil contents. Phagocytosis of apoptotic neutrophils by macrophages also promotes the production of anti-inflammatory factors, including transforming growth factor (TGF)-β [64]. Evidence for uptake of such apoptotic cells by macrophages in gout exists in the form of the Reiter cell, which is found in synovial fluid during acute gout attacks [65].

The role of monocyte-macrophage differentiation. Several observations imply that differentiated macrophages may play an important role in the resolution of the acute gout attack. MSU crystals found in asymptomatic joints of patients with hyperuricaemia and interval gout are usually present within macrophages and almost never within neutrophils [66]. This suggests that macrophages can interact with MSU crystals within the joint without triggering an inflammatory response. Within air pouches injected with MSU crystals, macrophage accumulation continues even after 48 h, when neutrophil infiltration has resolved [67]. Moreover, the inhibitory effect of apoptotic neutrophils described above provides evidence that certain phagocytic stimuli can induce an anti-inflammatory macrophage response.

The effect of differentiation upon the response of monocyte-macrophages to MSU crystals has been studied using a panel of mouse cell lines fixed at different stages of maturation (defined by expression of the markers F4/80 and BM8) [68]. There was close correlation between the level of expression of the surface markers and the capacity to phagocytose latex beads or MSU crystals. However, TNF-α production was not linked to phagocytic activity, since cell lines that were at an intermediate level of maturation expressed the highest concentrations of TNF-α. In contrast, the most mature macrophage lines (MH-S and IC-21) failed to produce TNF-α despite efficient phagocytosis of MSU crystals. Following exposure to MSU crystals, culture supernatants from partially differentiated macrophages, but not from the fully differentiated cell lines, stimulated endothelial activation. Zymosan, an alternative phagocytic stimulus, led to TNF-α production by IC-21 cells, indicating particle specificity of the response. Furthermore, in co-culture experiments, the release of TNF-α by IC-21 cells in response to zymosan was inhibited by a soluble factor released in response to MSU crystals, suggesting that the response to MSU crystals was actively anti-inflammatory rather than neutral.

These experiments using mouse cell lines have now been extended to a model in which human monocytes are differentiated in vitro to macrophages in the presence of autologous serum [69]. Following exposure to MSU crystals, undifferentiated peripheral blood monocytes secreted the cytokines TNF-α, IL-1β and IL-6, induced endothelial activation and promoted...
neutrophil recruitment under shear flow. However, differentiation of monocytes into mature macrophages over 5 days led to the loss of the capacity to release proinflammatory cytokines capable of activating endothelial cell adhesion molecule expression. As with IC-21 cells, this attenuated response to MSU crystals was particle-specific, zymosan stimulating macrophages to elicit a proinflammatory response. Again, co-culture of MSU crystals with zymosan inhibited zymosan-induced TNF-α production by differentiated macrophages but not immature monocytes (Fig. 2).

Macrophage production of anti-inflammatory cytokines may contribute to resolution of the acute attack. Overexpression of IL-10 using retrovirally transfected IL-10 inhibits macrophage production of TNF-α, macrophage inflammatory protein (MIP)-1α and MIP-1β in vitro, and MSU crystal-induced cellular infiltration in the murine air pouch model in vivo [70]. Thus, IL-10 has the ability to suppress the acute inflammatory response to MSU crystals. However, in vitro differentiated human macrophages do not express significant IL-10 on exposure to MSU crystals, suggesting that IL-10 may not play a major role in suppression of the inflammatory response in this model [71].

High levels of TGF-β1 have been demonstrated in the synovial fluid of patients with acute gout [72], and administration of TGF-β1 significantly inhibited leucocyte infiltration into air pouches injected with MSU crystals [73]. Further studies have now identified TGF-β1 as a key soluble factor in the suppression of MSU-induced inflammation by differentiated macrophages [71]. As monocytes differentiated in vitro towards a macrophage end-point, the loss of the capacity to secrete proinflammatory cytokines in response to MSU crystals was paralleled by a gain in the capacity to release TGF-β1. Functional effects of TGF-β1 in this model system include the suppression of (i) monocyte proinflammatory cytokine release in response to MSU crystals, (ii) endothelial cell activation in response to monocyte-derived cytokines, and (iii) macrophage release of TNF-α in response to zymosan. However, not all effects of TGF-β1 are suppressive and this growth factor may contribute to fibroblast proliferation and the physical encasing of crystals away from contact with leucocytes. Certainly, synovial tissue taken from patients with acute gout demonstrates marked fibroblast proliferation within the lining layer.

Taken together, these data support a role for monocyte differentiation in the resolution of acute inflammation in gout. As with any in vitro model, the interpretation of the data needs to be qualified by the possibility that macrophage differentiation in vitro may not faithfully reproduce the in vivo situation. In this respect, it is reassuring that monocytes and macrophages derived from a skin blister model showed the same disparity in cytokine secretion in response to MSU crystals as in vitro differentiated cells, the macrophage end-point appearing rather earlier in vivo (40 h as opposed to 5 days), consistent with the kinetics of a typical attack of gout (Fig. 3) [71].

### Tophaceous gout

It is well established that only a proportion of hyperuricaemic individuals develop gout [74]. Given that MSU crystals can be found within synovial mononuclear cells in asymptomatic joints of hyperuricaemic individuals [66], it seems possible that resident tissue macrophages may play a key role in maintaining the asymptomatic state in hyperuricaemia by clearing crystals as and when they form. In some individuals, persistent hyperuricaemia leads to the formation of tophaceous deposits of MSU crystals, typically in subcutaneous and periarticular areas. The reasons why some individuals are susceptible to the development of tophi is not known, but could include the formation of crystals at a rate that exceeds the handling capacity of tissue macrophages or possibly the failure of macrophages to differentiate to an end-point which does not show a proinflammatory response to crystal uptake.

Microscopically, tophi are granulomas of mono- and multinucleated macrophages surrounding a core of debris and MSU crystals, encased by dense connective tissue [75]. The gradation of size and urate content of gouty tophi suggests a progressive enlargement and maturation [75]. Within the tophus, macrophages express mature, late differentiation markers and show high levels of apoptosis. However, in associated perivascular regions, there is a predominance of mononucleated...
monocyte-macrophages expressing surface markers of recent migration [76]. These data suggest that the development of the gouty tophus is a dynamic process with a low level continuous recruitment, proinflammatory activation, maturation and turnover of monocyte-macrophages. This view is supported by the detection of TNF-α in tophaceous tissue [37, 76].

Tophi are frequently associated with tissue destruction of cartilage and bone. Several factors have been identified within tophaceous material that may contribute to such erosive disease. Monocyte-macrophages within the gouty tophus produce gelatinase A (MMP-2) and gelatinase B (MMP-9) [76]. These enzymes are capable of degrading type IV and type V collagen, elastin and gelatin. MMP-9 expression is induced in macrophages by MSU crystals in vitro in a dose-dependent manner [77]. Resident stromal cells also produce MMPs on exposure to MSU crystals, synovial fibroblasts producing collagenase (MMP-1) [78, 79] and chondrocytes producing stromelysin 1 (MMP-3) [80]. Release of such enzymes may play a role in degradation of matrix in articular structures adjacent to the tophus.

Conclusion

The inflammatory response in gout is characterized by initiation of the acute attack, leucocyte recruitment, amplification and subsequent resolution. These clinical manifestations of disease are due to complex interactions between various cell types, including mast cells, endothelial cells, neutrophils, macrophages and synovial fibroblasts. It is possible that the balance of monocytes and differentiated macrophages plays a key role in modulating the inflammatory response to MSU crystals. A hypothetical model of the role of monocyte-macrophage differentiation in gout is shown in Fig. 4. Further analysis of the pathways that regulate the cellular response to inflammatory micracrystals may identify potential therapeutic targets for the management of gout.

The authors have declared no conflicts of interest.

References


